Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 25, 2018

Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005)

Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalbán, Eva Havrdová, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen
First published April 9, 2018,
Ludwig Kappos
1University Hospital and University of Basel Basel Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krzysztof Selmaj
2Medical University of Lodz Lodz Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Bar-Or
3Center for Neuroinflammation and Therapeutics, and Multiple Sclerosis Division, University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giancarlo Comi
4San Raffaele Scientific Institute, Vita-Salute San Raffaele University Milan Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas Arnold
5NeuroRx Research and Montréal Neurological Institute, McGill University Montreal QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Steinman
6Beckman Center for Molecular Medicine, Stanford University Medical Center Stanford CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Peter Hartung
7Heinrich-Heine University Dusseldorf Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Montalbán
8University of Toronto, St Michael’s Hospital Toronto ON Canada
9Cemcat, Vall d’Hebron Hospital, Universitat Autonoma Barcelona Toronto ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Havrdová
10First Medical Faculty, Charles University Prague Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Sheffield
11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kartik Raghupathi
11Receptos, a wholly owned subsidiary of Celgene San Diego CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Cree
12UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Cohen
13Mellen Center for MS Treatment and Research, Cleveland Clinic Cleveland OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005)
Ludwig Kappos, Krzysztof Selmaj, Amit Bar-Or, Giancarlo Comi, Douglas Arnold, Lawrence Steinman, Hans-Peter Hartung, Xavier Montalbán, Eva Havrdová, James Sheffield, Kartik Raghupathi, Bruce Cree, Jeffrey Cohen
Neurology Apr 2018, 90 (15 Supplement) S36.005;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate efficacy of ozanimod in pre-planned patient subgroups.

Background: Ozanimod is an oral, once-daily immunomodulator selectively targeting sphingosine 1-phosphate receptors 1 and 5.

Design/Methods Two studies of ozanimod HCl 1 mg or 0.5 mg versus intramuscular interferon (IFN) beta-1a 30 μg for ≥12 months (SUNBEAM, NCT02294058, n=1346) or 24 months (RADIANCE, NCT02047734, n=1313) in relapsing multiple sclerosis (RMS).

Results: In SUNBEAM, adjusted annualized relapse rate (ARR) over the treatment period was lower with ozanimod 1 mg (0.195) and 0.5 mg (0.210) than IFN β-1a (0.338) among disease-modifying treatment (DMT)-naïve patients (69.5% of the population). ARR was also lower for ozanimod 1 mg (0.154) and 0.5 mg (0.299) than IFN β-1a (0.365) among DMT-experienced patients. Based on baseline Expanded Disability Status Scale (EDSS) category (≤3.5 or >3.5), ARR was lower with ozanimod 1 mg (0.170) and 0.5 mg (0.214) than IFN β-1a (0.369) in patients with baseline EDSS ≤3.5 (81.0% of population) and also lower with ozanimod 1 mg (0.145) and 0.5 mg (0.210) than IFN β-1a (0.215) among patients with EDSS >3.5. In RADIANCE, ARR over 24 months was lower with ozanimod 1 mg (0.157) and 0.5 mg (0.228) than IFN β-1a (0.246) among DMT-naïve patients (71.1% of population) and also lower for ozanimod 1 mg (0.205) and 0.5 mg (0.191) than IFN β-1a (0.357) among DMT-experienced patients. ARR was lower with ozanimod 1 mg (0.146) and 0.5 mg (0.183) than IFN β-1a (0.237) among patients with baseline EDSS ≤3.5 (84.6% of population) and lower with ozanimod 1 mg (0.334) and 0.5 mg (0.414) than IFN β-1a (0.531) among patients with EDSS >3.5. Additional subgroup analyses will be presented.

Conclusions: Ozanimod was effective in reducing ARR in DMT-naïve and -experienced patients and across baseline EDSS subgroups of mild and moderate disability, supporting its potential as an effective oral treatment in patients with RMS.

Study Supported by: Celgene

Disclosure: Dr. Kappos has received research support from Bayer HealthCare Pharmaceuticals, Biogen, F. Hoffmann-La Roche Ltd and Genentech,Novartis, Research grants from: the European Union, Roche Research Foundation, Swiss Multiple Sclerosis Society and Swiss National Research Foundation. Dr. Selmaj has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, Novartis, Merck, Roche. Dr. Bar-Or has nothing to disclose. Dr. Comi has nothing to disclose. Dr. Arnold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Biogen, F. Hoffmann-La Roche Ltd, MedDay, MedImmune, Mitsubishi, Novartis, Receptos/Celgene, Sanofi-Aventis. Dr. Arnold has received compensation for serving on the Board of Directors of NeuroRx Research. Dr. Steinman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene, Merck, Coherus, Atreca. Dr. Steinman has received compensation for serving on the Board of Directors of Atreca, Tolerion. Dr. Steinman has received royalty, license fees, or contractual rights payments from Tolerion. Dr. Steinman has received research support from Coherus, Celgene. Dr. Hartung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, GeNeuro, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Octapharma, Opexa Therapeutics, Teva Pharmaceuticals, MedImmune, Bayer HealthCare, Forward Pharma, and Roche. Dr. Montalban has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Oryzon, Roche, Sanofi and Teva Pharmaceutical.. Dr. Havrdova has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Biogen, Celgene, Merck, Novartis, Sanofi Genzyme and Teva.. Dr. Sheffield has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene. Dr. Raghupathi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene. Dr. Cree has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Biogen, EMD Serono, GeNEuro, Novartis, Sanofi Genzyme. Dr. Cree has received research support from Acorda, Hoffman La Roche, MedImmune, Novartis, Receptos and Teva. Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adams, Celgene.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise